SciClone Pharmaceuticals, Inc. (SciClone) is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. Its business and corporate strategy is focused primarily on the People’s Republic of China (China). SciClone operates in two geographic segments, which include China and the rest of the world, including its operations in the United States and Hong Kong. The Company’s lead product is ZADAXIN (thymalfasin) is approved in 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant and certain cancers. SciClone’s marketed portfolio also includes Depakine, Tritace, Stilnox and Aggrastat. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).